Even though they led for practically the entire game, the final quarter was filled with drama. Germantown cut the Olive Branch lead to 62-61 with just under 30 seconds to play before game MVP Rhema Pegues slammed the door with a couple of free throws.
“I’m just glad it’s over with,” Olive Branch coach Jason Thompson said. “We didn’t have our best stuff, but hey, sometimes it works out like that. All I can say is to God goes the glory. Those kids laid it on the line and they brought it at the end. They made shots, made free throws and did what they had to do to stay ahead, and as long as we had the lead, I felt like we were going to be okay.”
About Tarsus Pharmaceuticals, Inc.
Tarsus Pharmaceuticals, Inc. is a late clinical-stage biopharmaceutical company whose mission is to discover and deliver breakthrough treatments to transform the lives of patients with common and poorly treated diseases, starting with the eye. It is advancing its pipeline to address several diseases across therapeutic categories including eye care, dermatology, and other diseases with high unmet needs. Its lead product candidate, TP-03, is a novel therapeutic in Phase 2b/3 that is being developed for the treatment of Demodex blepharitis.
Forward-Looking Statements
Statements in this press release about future expectations, plans and prospects, as well as any other statements regarding matters that are not historical facts, may constitute forward-looking statements. The words, without limitation, believe, contemplate, continue, could, estimate, expect, intend, may, might, plan, potential, predict, project, should, ta
Tarsus Pharmaceuticals, Inc. Announces Type C Meeting with FDA Regarding NDA Submission Requirements for Lead Candidate TP-03
The Company began enrolling patients in Saturn-1 in September 2020 and expects to initiate its second pivotal registration trial, Saturn-2, in 2021
IRVINE, Calif., Dec. 23, 2020 (GLOBE NEWSWIRE) Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), a late clinical-stage biopharmaceutical company whose mission is to discover and deliver breakthrough treatments to transform the lives of patients with common and poorly treated diseases, starting with the eye, today announced that it received written minutes from the (Type C) meeting held on December 8 with the United States Food and Drug Administration (FDA). The meeting was held to align on specific NDA submission requirements for TP-03, a novel therapeutic in development for the treatment of Demodex blepharitis, and the Company believes it received collaborative and productive guidance.